AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Knowing when to prepare for retirement is crucial. Explore key timing tips to help you plan effectively for your golden years.
24,806 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
SpaceX sits on a colossal cash hoard, but does $100 billion guarantee long-term growth? This guide breaks down what t...
Vertex is pursuing Crinetics with a substantial all-cash offer. This deep dive breaks down what the $10 billion bid m...
In 2026, equal-weight XSD and cap-weight SMH offer contrasting bets on AI-driven chipmakers. This article analyzes ho...
Ciena’s shares jumped sharply in the first half of 2026. This article dives into the AI-driven demand for optical net...
A high-profile insider move by Pinterest’s leadership drew attention from investors. This deep dive explains what the...
When a leading floor-care company hits a rough patch, headlines follow. This look explains why Tennant stock plummeti...
Mercer (MERC) 2026 earnings outlook explained. This analysis breaks down Q1 results, key metrics, and what to expect ...
XRP remains under scrutiny as 2026 unfolds, with faster settlement times and evolving regulation shaping its appeal. ...
When a smart-home name rallies, traders pay attention. This piece breaks down why resideo technologies stock popped o...
When a juggernaut like Fortnite cools its engagement, the ripple effect hits the entire company. This piece digs into...
Amazon plans an unprecedented AI data-center buildout, with a $200 billion capex target for 2026. This article unpack...